Evidence map›Paper›PMID 29096715›Full record

ArticleStem cell research & therapy2017

Differentiation of human umbilical cord Wharton's jelly-derived mesenchymal stem cells into endometrial cells.

Qin Shi, JingWei Gao, Yao Jiang, Baolan Sun, Wei Lu, Min Su, Yunzhao Xu, Xiaoqing Yang, Yuquan Zhang

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Mesenchymal stem cells-derived secretome and extracellular vesicles: perspective and challenges in cancer therapy and clinical applications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Qin ShiDepartment of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, People's Republic of China.
JingWei GaoDepartment of Obstetrics and Gynecology, Suzhou Municipal Hospital, Soochow, People's Republic of China.
Yao JiangDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital of Soochow University, Soochow, People's Republic of China.
Baolan SunDepartment of Pediatrics, Affiliated Hospital of Nantong University, Nantong, People's Republic of China.
Wei LuDepartment of Hematology, Affiliated Hospital of Nantong University, Nantong, People's Republic of China.
Min SuDepartment of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, People's Republic of China.
Yunzhao XuDepartment of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, People's Republic of China.
Xiaoqing YangDepartment of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, People's Republic of China. ntyxq169@126.com.
Yuquan ZhangDepartment of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, People's Republic of China. jsnt_zhangyuquan@163.com.
Nantong University · CNAffiliated Hospital of Nantong University · CNSecond Affiliated Hospital of Soochow University · CNSuzhou Municipal Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWharton's jelly-derived mesenchymal stem cells (WJ-MSCs) are a novel and promising strategy for tissue engineering because of their ability to differentiate into many cell types. We characterized the differentiation of WJ-MSCs into endometrial epithelial cell (EEC)-like and endometrial stromal cell (ESC)-like cells and assessed the effect of 17β-estradiol and 8-Br-cAMP on the differentiation system.

methodsWJ-MSCs were treated in two ways to differentiate into EEC-like and ESC-like cells respectively: cocultured with ESCs in control/differentiation medium (17β-estradiol, growth factors); and cultured in control/differentiation medium (8-Br-cAMP alone or 8-Br-cAMP plus 17β-estrogen and growth factors). Three signaling pathway inhibitors (SB203580, PD98059, H89) were used to investigate the mechanism of WJ-MSC differentiation into ESC-like cells. Immunofluorescence, western blot and flow cytometry analyses were used to analyze expression of epithelial markers and stromal cell markers. Enzyme-linked immunosorbent assays were used to test the production of secretory proteins associated with the differentiation of ESC-like cells.

results17β-estradiol at 1 μM downregulated vimentin and CD13 and upregulated cytokeratin and CD9 proteins, promoting the differentiation of WJ-MSCs into EEC-like cells in the coculture system. 8-Br-cAMP at 0.5 mM upregulated vimentin and CD13 and downregulated CK and CD9, promoting the differentiation of WJ-MSCs into ESC-like cells. Prolactin (PRL) and insulin-like growth factor-binding protein 1 (IGFBP1) were upregulated and the protein kinase A (PKA) signaling pathway was activated, whereas extracellular signal-regulated (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) were not affected.

conclusions17β-estradiol at 1 μM is a good inducer for facilitating the differentiation of WJ-MSCs into EEC-like cells. 8-Br-cAMP plus estrogen and growth factors can induce the differentiation of WJ-MSCs into ESC-like cells. During the differentiation of WJ-MSCs into ESC-like cells, PRL and IGFBP1 were upregulated by the treatment and the PKA signaling pathway was activated, whereas ERK1/2 and p38 MAPK were not affected. These findings suggest a promising approach to the treatment of endometrial damage and other endometrial diseases and suggest new applications for WJ-MSCs in clinical practice.

Indexed as

8-Bromo Cyclic Adenosine MonophosphateCD13 AntigensCell DifferentiationCell ProliferationCyclic AMP-Dependent Protein KinasesEndometriumEpithelial CellsEstradiolFemaleFlavonoidsGene Expression RegulationHumansImidazolesInsulin-Like Growth Factor Binding Protein 1Intercellular Signaling Peptides and ProteinsIsoquinolines2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one8-Bromo Cyclic Adenosine MonophosphateCD13 AntigensCD9 protein, humanCyclic AMP-Dependent Protein KinasesEstradiolFlavonoidsIGFBP1 protein, humanImidazolesInsulin-Like Growth Factor Binding Protein 1Intercellular Signaling Peptides and ProteinsIsoquinolinesKeratinsMAPK1 protein, humanMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamideProlactinPyridinesSB 203580SulfonamidesTetraspanin 29VimentinDifferentiationEndometrial glandular epithelial cellsEndometrial stromal cellsWharton’s jelly-derived mesenchymal stem cells

Identifiers

PMID29096715
PMCPMC5667478
OpenAlexW2766156193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.